Press
RCOphth continue to express concern regarding junior doctors contract
The Royal College of Ophthalmologists remains concerned about the continuing dispute between the BMA and the Department of Health regarding the junior doctors contract. We continue to urge all sides to come together for further constructive negotiation without pre-conditions on either side. Independent arbitration may help to break the gridlock and this would be welcome. In
Bayer Ophthalmology Honours launched at Annual Congress 2015
Bayer launches its new awards programme which aims to recognise and celebrate outstanding work in ophthalmology in the UK Newbury, Monday 18 May 2015 – A new awards programme, Bayer Ophthalmology Honours, has been launched today by Bayer HealthCare at the Royal College of Ophthalmologists’ Annual Congress. The programme aims to recognise and celebrate, on an
2014 winners for the Bayer Educational Grant Award announced
Bayer Healthcare Press Release Newbury, Thursday 5 March, 2015 The Royal College of Ophthalmologists (RCOphth), in partnership with Bayer HealthCare, today announces the 2014 winners of the inaugural Bayer Educational Grant Awards. This awards programme, sponsored by Bayer, aims to support ophthalmologists with an educational grant to present their work at educational meetings in the UK
NHS Clinical Commissioners co-ordinate support from CCGs to review use of Avastin to treat wet AMD
College Statement In response to the public letters sent by the NHS Clinical Commissioners to Secretary of State for Health, cc. Chair of NICE; Simon Stevens at NHS England; and the Chair of the GMC and signed by the Clinical Chair / Lead Clinician of 120 CCGs regarding the use of Avastin to treat wet AMD. The Royal
Use of Avastin (bevacizumab) in age related macular degeneration
Updated Statement from The Royal College of Ophthalmologists In 2011 a working group of The Royal College of Ophthalmologists released a statement regarding the use of Avastin (bevacizumab) in medical ophthalmology. It found that Avastin and Lucentis (ranibizumab) were equally effective in the treatment of neovascular age-related macular degeneration (AMD) and that there was no